Nocion, chasing GSK, pulls in $62M for chronic cough drug

Investors have poured $62 million into a biotechnology startup developing a drug to treat chronic cough.

Nocion Therapeutics, headquartered in Watertown, Massachusetts, announced Monday it completed a Series B fundraise that was co-led by Arkin Bio Capital and Monograph Capital and included participation from Canaan Partners, F-Prime Capital and others. The company has now raised $122 million since its launch in 2018.